Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting

Rhea-AI Summary

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology firm, announced batiraxcept data presentations at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting from June 2-6, 2023. Key details include:

• Poster Presentation: Phase 2 study of batiraxcept in advanced clear cell renal cell carcinoma (ccRCC) by Kathryn Beckermann, MD, PhD, scheduled for June 3, 2023, from 8:00 AM - 11:00 AM CDT.
• Abstract Publication: Batiraxcept in pancreatic adenocarcinoma accepted for publication.

Batiraxcept, an AXL inhibitor, has received Fast Track Designation from the FDA for ccRCC and platinum-resistant ovarian cancer. It is undergoing Phase 3 trials for ovarian cancer and Phase 1b/2 trials for ccRCC and pancreatic adenocarcinoma.

Positive

• Batiraxcept data accepted for presentation at ASCO 2023, indicating ongoing clinical interest.
• Fast Track Designation by FDA for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer.
• Ongoing Phase 3 trials for batiraxcept in platinum-resistant ovarian cancer, suggesting potential future revenue streams.

Negative

• None.

HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually. In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma was accepted for publication.

Title:	Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)
Presenter:	Kathryn Beckermann, MD, PhD
Abstract Number:	4534
Format/Session:	Poster; Genitourinary Cancer—Kidney and Bladder
Session Date/Time:	Saturday, June 3, 2023, 8:00 AM – 11:00 AM CDT

Title:	Phase 1b Batiraxcept (AVB-S6-500, BT) plus Gemcitabine (G) and Nab-paclitaxel (NP) as first-line treatment (1L) for pancreatic adenocarcinoma (PDAC)
Abstract Number:	e16258
Format/Session:	Publication Only

The poster will be available on the “Publications” section of the Aravive website when the ASCO embargo is released on May 25, 2023 at 4:00 PM CDT.

About Aravive
Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic adenocarcinoma (NCT04983407). The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Additional information at www.aravive.com.

Investor Relations Contact:

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

FAQ

What is the significance of the ASCO 2023 Annual Meeting for Aravive?

The ASCO 2023 Annual Meeting is crucial for Aravive as it provides a platform to present batiraxcept data, enhancing visibility among oncology professionals.

What is batiraxcept, and how is it being studied?

Batiraxcept is an AXL inhibitor being studied in various trials, including a Phase 3 trial for platinum-resistant ovarian cancer and Phase 1b/2 trials for clear cell renal cell carcinoma and pancreatic adenocarcinoma.

When will the batiraxcept poster be available for public viewing?

The batiraxcept poster presentation will be available on Aravive's website after the ASCO embargo lifts on May 25, 2023, at 4:00 PM CDT.

Who is presenting the batiraxcept data at ASCO 2023?

The batiraxcept data will be presented by Kathryn Beckermann, MD, PhD, at the ASCO 2023 Annual Meeting.

What designations have been granted to batiraxcept?

Batiraxcept has received Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission for its treatment indications.